Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
T | 0.810 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.810 | CausalMutation | CLINVAR | ||||||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | 23414587 | 2013 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | 22761467 | 2012 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. | 23538902 | 2013 |
|||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 |
|||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. | 20149136 | 2010 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | 23614898 | 2013 |
|||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | NRAS-mutant melanoma: response to chemotherapy. | 21576590 | 2011 |
|||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. | 23538902 | 2013 |
|||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | 23614898 | 2013 |
|||||||
|
|
A | 0.800 | CausalMutation | CLINVAR | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. | 23569304 | 2013 |
|||||||
|
|
C | 0.800 | CausalMutation | CLINVAR | ||||||||||
|
|
G | 0.800 | CausalMutation | CLINVAR | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. | 23569304 | 2013 |